retatrutide fda status 2025 approval: status, clinical trial results, and when it could be available What Is Retatrutide? New Weight

This review also addresses recent advances in the development of other dual and triple receptor agonists

Rapid improvement in blood sugar control can temporarily worsen diabetic retinopathy, a diabetes-related eye condition

Postgrad Med J 96(1133):156161 Singh K, Aulakh SK, Nijjar GS, Singh S, Sandhu APS, Luthra S, et al (2024) Rebalancing the gut: glucagon-like peptide-1 agonists as a strategy for obesity and metabolic health

When released in response to food intake, GLP-1 helps to: Increase insulin secretion Decrease glucagon secretion Slow gastric emptying Promote satiety By activating GLP-1 receptors in the brain and gastrointestinal tract, these medications help individuals feel fuller for longer periods, ultimately leading to reduced caloric intake and weight loss

[DOI] [PubMed] [Google Scholar] Mascitelli L, Pezzetta F, Sullivan JL